CEO & Chairman of the Board's Message - "Building & Enhancing Shareholder Value"

The company having truncated its last project in Croatia is continuing to seek and review s advanced Pharmaceutical & Medical projects.  I believe that the pharmaceutical and medical sector is going to continue to flourish, especially with an aging population growing globally, and with the expected and imminent drop in the interest rates around the world. 

The foregoing opinion & statement certainly is a forward-looking statement, and since I'm about to make more of the same, I urge you to read the  "Cautionary Disclaimer" available on the Company's website, and as referred to again later in this presentation.

The Company, having faced the past economic difficult times caused due to the Covid epidemic and subsequent high interest rates to fight inflation,  and due to Croatia not legislating the necessary laws on medical marijuana use on a timely basis  terminated its initial project in Croatia, part of the European Union ("EU"),  Additionally, the Company controlled it costs to a minimal level to restrict shareholder dilution.  With the interest rates finally starting to recede, the Company once again has commenced its pursuit to acquire  advanced pharmaceutical and medical assets, especially with emphasis on artificial intelligence ("AI"). 

Based on current global economic, social, political, environmental & ecological dynamics & the transforming trends emerging at a time when the world population growth, especially of the elderly reaches new highs, the demand for pharmaceutical and medical assets, especially catering to the elderly, will reach highest levels both in the established westernized economies and the emerging economies.  And, this is all happening when the pharmaceutical sector needs to regroup after the Covid issues; somewhat of a disarray.

Note: Pursuant to the Company's business plan, when the Company first was created as a reporting company seeking a listing on a stock exchange in 2020, immediately following the onset of the Covid epidemic, the last Pharmaceutical project in Croatia was acquired at what management believes to be exceptionally low price, representing "zero cost"; and hence without significant dilution to shareholders. upon the completion of an extensive review of  global demand for various types of pharmaceutical & medical products. 

The right time to Acquire Advanced Pharmaceutical & Medical projects is "Now".  Our Team can accomplish it, and again, with shareholder/investor support.